OMER logo

OMER Omeros Corporation

NASDAQ Global Market · Biotechnology · Healthcare

$17.55
+0.63 (+3.72%)

Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dy…

Market Cap: $1.27Bwww.omeros.com

Price

No data yet.

Social Signal Score

61
5d
73
1 mentions
—
30d
55
5 mentions
—
60d
57
6 mentions
—
90d
59
8 mentions
—
news: 8

Analyst Ratings

19 analysts
Buyconsensus
Strong Buy 1Buy 11Hold 5Sell 2Strong Sell 0
Avg price target$27.5+56.7%
Low $22Median $27.5High $33
Current Consensus

Revenue

$28.53M+152.72%
$-79.89M$-42.12M$-4.35M$33.42M
Sep 2016Jun 2026

Analyst Estimates

FY2025
$-2.03
$-2.46–$-1.64
2 analysts
FY2026
$0.82
$0.67–$1.00
2 analysts
FY2027
$1.06+28% YoY
$0.21–$1.90
2 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Gregory A. Demopulos
Sector
Healthcare
Industry
Biotechnology
Employees
175
Beta
2.57
Country
US
Piotroski score
6 / 9 (Middling)
Altman Z-score
0.08
www.omeros.com